Literature DB >> 6427972

Mouse monoclonal antibody detects a new polymorphic Ia determinant other than HLA-DR antigen: a possible allele of DC-1.

H Maeda.   

Abstract

Using a hybridoma technique, a monoclonal antibody ( TA10 ) reactive with a new polymorphic B-cell antigen was obtained. The TA10 antibody reacted with 12 (24%) of B cells from 50 healthy individuals, but not with T cells. In contrast with the HLA-DR antigen, the TA10 antigen was preferentially detected on B cells, but not on monocytes. The reactive pattern of TA10 was closely associated with DR5 and its related DR antigen NJ2 , and also found with DR4 or DRw9 . The linkages of TA10 to these DR antigens were confirmed in the family study, indicating that the TA10 antigen is controlled by a closely linked but distinct locus from HLA-DR. Furthermore, two-dimensional gel analysis demonstrated that the TA10 determinant was expressed on a class II molecule whose heavy and light chains were different from those carrying the DR determinant. Thus, this monoclonal antibody might detect an allele of DC-1 which is found in association with DR5 and DRw6.2.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6427972     DOI: 10.1111/j.1399-0039.1984.tb00027.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  10 in total

1.  Serological discrimination of DR4 haplotypes by radioimmunoassay.

Authors:  N Tanigaki; R Tosi; G B Ferrara
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

2.  Identification of a polymorphic variant associated with HLA-DQw3 and characterized by specific restriction sites within the DQ beta-chain gene.

Authors:  S J Kim; S L Holbeck; B Nisperos; J A Hansen; H Maeda; G T Nepom
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

3.  Dissection of HLA class II haplotypes in HLA-DR4 homozygous individuals.

Authors:  M G Tilanus; B Morolli; M C van Eggermond; G M Schreuder; R R de Vries; M J Giphart
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

4.  A diabetes-susceptible HLA haplotype is best defined by a combination of HLA-DR and -DQ alleles.

Authors:  M J Sheehy; S J Scharf; J R Rowe; M H Neme de Gimenez; L M Meske; H A Erlich; B S Nepom
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

5.  Detection of a novel HLA-DQ specificity. II. Cellular analysis by cytotoxic T-cell clones.

Authors:  H Kojima; Y Fukasawa; N Ishikawa; Y Tajima; A Wakisaka; M Aizawa
Journal:  Immunogenetics       Date:  1988       Impact factor: 2.846

6.  Immunochemistry of the HLA class II molecules isolated from a mouse cell transfected with DQ alpha and beta genes from a DR4 haplotype.

Authors:  N Tanigaki; R Tosi; J L Strominger; J Cooper
Journal:  Immunogenetics       Date:  1987       Impact factor: 2.846

7.  Molecular diversity of HLA-DQ. DQ alpha and beta chain isoelectric point differences and their relation to serologically defined HLA-DQ allospecificities.

Authors:  R E Bontrop; E J Baas; N Otting; G M Schreuder; M J Giphart
Journal:  Immunogenetics       Date:  1987       Impact factor: 2.846

8.  HLA-DR, DQ, and DX alpha RFLPs and their associations with serologically defined HLA-DR and -DQ antigens.

Authors:  J Awad; C Navarrete; J A Sachs; H Festenstein; P G Cassell; M J Niven; G Hitman
Journal:  Immunogenetics       Date:  1988       Impact factor: 2.846

9.  Association of HLA antigens with differential responsiveness to Mycobacterium w vaccine in multibacillary leprosy patients.

Authors:  R Rani; S A Zaheer; N R Suresh; R Walia; S K Parida; A Mukherjee; R Mukherjee; G P Talwar
Journal:  J Clin Immunol       Date:  1992-01       Impact factor: 8.317

10.  HLA-DO polymorphism associated with resistance to type I diabetes detected with monoclonal antibodies, isoelectric point differences, and restriction fragment length polymorphism.

Authors:  G M Schreuder; M G Tilanus; R E Bontrop; G J Bruining; M J Giphart; J J van Rood; R R de Vries
Journal:  J Exp Med       Date:  1986-09-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.